Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion

BACKGROUNDS AND AIMS: Molecular-targeted agents are acceptable standards to treat advanced-stage hepatocellular carcinoma (HCC), however, their therapeutic benefit, ie, sorafenib, was significantly offset in case of major vessel invasion. Liver-directed concurrent chemo-radiotherapy (LD-CCRT) provid...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Hepatocell Carcinoma
Autores principales: Han, Sojung, Lee, Hye Won, Park, Jun Yong, Kim, Seung Up, Kim, Do Young, Ahn, Sang Hoon, Han, Kwang-Hyub, Seong, Jinsil, Won, Jong Yun, Han, Dai Hoon, Kim, Beom Kyung
Formato: Artigo
Lenguaje:Inglês
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7751588/
https://ncbi.nlm.nih.gov/pubmed/33365287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S276528
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares